LITAF and metabolic dysfunction-associated steatohepatitis: Our data indicates that LITAF can be an LPS-induced pro-inflammatory and pro-fibrogenic mediator during NASH development and suggests that this transcription factor contributes to the liver damage caused by HSC activation.